Zacks Research Has Optimistic Outlook of PBYI Q1 Earnings

Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) - Equities researchers at Zacks Research increased their Q1 2026 earnings estimates for Puma Biotechnology in a research report issued to clients and investors on Wednesday, April 30th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings of $0.07 per share for the quarter, up from their prior forecast of $0.06. The consensus estimate for Puma Biotechnology's current full-year earnings is $0.31 per share. Zacks Research also issued estimates for Puma Biotechnology's FY2026 earnings at $0.28 EPS and Q1 2027 earnings at $0.13 EPS.

Several other research analysts have also recently weighed in on PBYI. StockNews.com cut Puma Biotechnology from a "strong-buy" rating to a "buy" rating in a research report on Saturday. HC Wainwright restated a "buy" rating and set a $7.00 target price on shares of Puma Biotechnology in a research note on Friday, February 28th.

Puma Biotechnology Stock Down 4.4 %

Shares of PBYI traded down $0.14 during midday trading on Thursday, hitting $3.07. 198,245 shares of the company's stock traded hands, compared to its average volume of 441,304. The firm's fifty day moving average is $3.13 and its 200-day moving average is $3.04. The stock has a market capitalization of $152.37 million, a price-to-earnings ratio of 6.40 and a beta of 1.29. Puma Biotechnology has a 1 year low of $2.23 and a 1 year high of $5.20. The company has a current ratio of 1.42, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46.

Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported $0.39 earnings per share for the quarter, beating the consensus estimate of $0.10 by $0.29. The company had revenue of $59.10 million for the quarter, compared to analyst estimates of $52.50 million. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%.

Hedge Funds Weigh In On Puma Biotechnology

Several large investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC increased its stake in shares of Puma Biotechnology by 167.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 10,137 shares of the biopharmaceutical company's stock worth $31,000 after buying an additional 6,351 shares during the last quarter. Gateway Wealth Partners LLC acquired a new position in Puma Biotechnology in the 4th quarter valued at approximately $31,000. Graham Capital Management L.P. acquired a new stake in Puma Biotechnology during the fourth quarter valued at approximately $33,000. ProShare Advisors LLC bought a new position in Puma Biotechnology in the 4th quarter valued at $36,000. Finally, C2C Wealth Management LLC acquired a new position in shares of Puma Biotechnology during the fourth quarter valued at $37,000. 61.29% of the stock is currently owned by hedge funds and other institutional investors.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.